|Reminder: Exelixis Announces Data Presentations, Webcast of Investor Briefing in Conjunction With 2012 ASCO Annual Meeting|
-- Oral Presentations for Medullary Thyroid Cancer,
Castration-Resistant Prostate Cancer, Renal Cell Carcinoma and
-- Investor Briefing Webcast Will Review, Provide Context for Data
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May. 16, 2012--
Exelixis, Inc. (NASDAQ:EXEL) reiterated its slate of activities in
conjunction with the 2012 American Society of Clinical Oncology (ASCO)
Annual Meeting, which will be held June 1-5, 2012, in Chicago, Illinois.
Clinical data for cabozantinib will be featured in four oral
presentations, four poster discussion presentations, and one general
poster presentation. The company will also host an investor briefing
that will be webcast live on Monday, June 4, 2012.
The full roster of cabozantinib data presentations expected at the
meeting appears below (all times Central Daylight). As data are
presented at the meeting, the accompanying presentations and/or posters
will be made available online via the Events page under Resources on www.exelixis.com.
"Efficacy of cabozantinib (XL184) in patients (pts) with metastatic,
refractory renal cell carcinoma (RCC)" (Abstract #4504)
K. Choueiri, Lank Center for Genitourinary Oncology, Dana-Farber
Cancer Institute/Brigham and Women's Hospital, Harvard Medical School,
Oral Abstract Session: Genitourinary Cancer
Saturday, June 2; 4:15 p.m.
"Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results
from a phase II randomized discontinuation trial (RDT)" (Abstract
Dr. Chris Verslype, Hepatology, University Hospitals
Oral Abstract Session:
Gastrointestinal (Noncolorectal) Cancer
Saturday, June 2; 5:15
"An international, double-blind, randomized, placebo-controlled phase
III trial (EXAM) of cabozantinib (XL184) in medullary thyroid
carcinoma (MTC) patients (pts) with documented RECIST progression at
baseline" (Abstract #5508)
Schöffski, Department of General Medical Oncology, Catholic University
Clinical Science Symposium: Targeting
Therapeutics for Thyroid Cancers
Monday, June 4; 11:30 a.m.
"Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration
resistant prostate cancer (mCRPC): Results from a phase II
nonrandomized expansion cohort (NRE)" (Abstract #4513)
R. Smith, Massachusetts General Hospital Cancer Center, Boston, MA
Abstract Session: Genitourinary Cancer (Prostate)
5; 11:00 a.m.
Poster Discussion Presentations
"Activity of cabozantinib (XL184) in metastatic breast cancer (MBC):
Results from a phase II randomized discontinuation trial (RDT)"
(Abstract #535; Poster Board #25)
Dr. Eric P.
Winer, Dana-Farber Cancer Institute, Boston, MA
Discussion Session: Breast Cancer-HER2/ER
Saturday, June 2; 1:15
p.m. - 5:15 p.m. (discussion to follow)
"Activity of cabozantinib (XL184) in metastatic melanoma: Results from
a phase II randomized discontinuation trial (RDT)" (Abstract #8531;
Poster Board #20)
Dr. Michael S. Gordon, Pinnacle Oncology
Hematology, Scottsdale, AZ
Poster Discussion Session:
Saturday, June 2; 1:15 p.m. - 5:15 p.m.
(discussion to follow)
"Investigator sponsored trial of efficacy and tolerability of
cabozantinib (cabo) at lower dose: A dose-finding study in men with
castration-resistant prostate cancer (CRPC) and bone metastases"
(Abstract #4566; Poster Board #20)
Dr. Richard J.
Lee, Massachusetts General Hospital Cancer Center, Boston, MA
Discussion Session: Genitourinary (Prostate) Cancer
4; 8:00 a.m. - 12:00 p.m. (discussion to follow)
"Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a
phase II randomized discontinuation trial (RDT)" (Abstract #7514;
Poster Board #4)
Dr. Beth A. Hellerstedt, US Oncology
Research, LLC, McKesson Specialty Health, The Woodlands, TX, and Texas
Oncology, Central Austin Cancer Center, Austin, TX
Discussion Session: Lung Cancer - Non-small Cell Metastatic
June 5; 8:00 a.m. - 12:00 p.m. (discussion to follow)
"Antitumor activity of cabozantinib (XL184) in a cohort of patients
(pts) with differentiated thyroid cancer (DTC)" (Abstract #5547;
Poster Board #22G)
Dr. Maria E. Cabanillas, University of
Texas MD Anderson Cancer Center, Houston, TX
Session: Head and Neck Cancer
Saturday, June 2; 1:15 p.m. - 5:15
Details on May 16th
Release of 2012 ASCO Annual Meeting Abstracts
The 2012 ASCO Annual Meeting abstracts featuring cabozantinib will be
posted publicly on www.asco.org
today, Wednesday, May 16, 2012, at 6:00 p.m. EDT. These abstracts were
submitted to ASCO in early 2012 and do not incorporate data and new
findings generated since that time. The latest and most up-to-date
clinical data will be delivered during the investigators’ presentations
at the meeting itself, at the dates and times listed above.
Investor Briefing at the 2012 ASCO Annual
Exelixis will hold an investor briefing that will be webcast live on
Monday, June 4, 2012, from 6:30-8:30 p.m. CDT. During the briefing,
Exelixis management and other presenters will review and provide context
for the latest clinical data for cabozantinib in medullary thyroid
cancer, castration-resistant prostate cancer, and other tumor types, as
presented at the ASCO Annual Meeting. In addition to Exelixis
management, participants in the briefing will include:
Dr. Jose Baselga, Massachusetts General Hospital Cancer Center,
Dr. Toni Choueiri, Dana-Farber Cancer Institute/Brigham and Women's
Hospital, Boston, MA
Dr. Karim Fizazi, Institut Gustave Roussy, Paris, France
Dr. Daniel George, Duke University Medical Center, Durham, NC
Dr. Patrick Schöffski, Catholic University Leuven, Belgium
Dr. Steven Sherman, MD Anderson Cancer Center, Houston, TX
Dr. Matthew Smith, Massachusetts General Hospital Cancer Center,
The webcast will be accessible via the Event Calendar page under
Investors at www.exelixis.com.
An archived replay of the webcast will be available on the Event
Calendar page under Investors at www.exelixis.com
and audio-only via phone until 11:59 p.m. EDT/8:59 p.m. PDT on July 11,
2012. Access numbers for the audio-only phone replay are: 888-286-8010
(domestic) and 617-801-6888 (international); the passcode is 35434695.
Exelixis, Inc. is a biotechnology company committed to developing small
molecule therapies for the treatment of cancer. Exelixis is focusing its
proprietary resources and development efforts exclusively on
cabozantinib (XL184), its most advanced product candidate, in order to
maximize the therapeutic and commercial potential of this compound.
Exelixis believes cabozantinib has the potential to be a high-quality,
broadly-active, differentiated pharmaceutical product that can make a
meaningful difference in the lives of patients. Exelixis has also
established a portfolio of other novel compounds that it believes have
the potential to address serious unmet medical needs, many of which are
being advanced by partners as part of collaborations. For more
information, please visit the company's web site at http://www.exelixis.com.
Source: Exelixis, Inc.
Charles Butler, 650-837-7277